Pre-made Bexmarilimab benchmark antibody ( Whole mAb, anti-STAB1 therapeutic antibody, Anti-CLEVER-1/FEEL-1/FEEL1/FELE-1/FEX1/SCARH2/STAB-1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Bexmarilimab biosimilar, Whole mAb, Anti-STAB1 Antibody: Anti-CLEVER-1/FEEL-1/FEEL1/FELE-1/FEX1/SCARH2/STAB-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Faron's wholly-owned novel precision cancer immunotherapy drug candidate, bexmarilimab, targets the Clever-1 receptor, known to be expressed on immunosuppressive macrophages in the tumour microenvironment and circulating in soluble form, and which is capable of directly inhibiting T-cell activation.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-066-1mg	1mg	3090
GMP-Bios-ab-066-10mg	10mg	Inquiry
GMP-Bios-ab-066-100mg	100mg	Inquiry
GMP-Bios-ab-066-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Bexmarilimab biosimilar, Whole mAb, Anti-STAB1 Antibody: Anti-CLEVER-1/FEEL-1/FEEL1/FELE-1/FEX1/SCARH2/STAB-1 therapeutic antibody
INN Name	Bexmarilimab
Target	STAB1
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Faron Pharmaceuticals
Conditions Approved	na
Conditions Active	Solid tumours;Cancer;Immunocompromised infections;Pertussis;Tuberculosis
Conditions Discontinued	na
Development Tech	na